Company intelligence / Profile preview

Clade Therapeutics

Boston, Massachusetts, United Stateslife-sciences-europe.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Clade developed a proprietary platform for generating “cloaked” iPSC-derived αβ T, NK, and B cells designed for allogeneic, off-the-shelf use. Its lead programs targeted cancer and autoimmune diseases. The company was acquired by Century Therapeutics in April 2024 to enhance Century’s Allo-Evasion™ platform and expand its pipeline with next-generation engineered T cell programs. No clinical results have been published.

Therapeutic areas: OncologyImmunology
Modalities: Induced pluripotent stem cell (iPSC)-derived immune cellsEngineered T cellsNK cellsB cells
Industry: Biotech

Beyond the preview

Go deeper on Clade Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clade Therapeutics.

Explore the full profile